Case Study

Alofisel P3 Cell Therapy Facility

Source: CAI
1456216634-digital-pathway

CAI was chosen to aid Takeda GC with a faltering Commissioning, Qualification, and Validation (CQV) project at its new Advanced Therapy Medicinal Product (ATMP) manufacturing facility (P3) in Grange Castle. The project was overdue and over budget, with CAI tasked with the qualification of Production Rooms 1 and 2 and their associated process equipment. Despite various issues such as problems with the document management system, vendor commissioning/validation, change management system, and communication, CAI managed to deliver the project on time. This success resulted in CAI securing additional work worth €0.6m and broadening their service offerings to Takeda GC. The P3 facility was the first ATMP facility in Ireland, signifying a significant accomplishment for CAI.

access the Case Study!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Bioprocess Online